Benzodiazepine Use
Conditions
Brief summary
This cluster-randomized study aims to evaluate the impact of a web-based clinical support tool on adherence to recommended maximum durations for benzodiazepine prescriptions among new users in primary care. General practitioners (GPs) participating in the study will have access to the website, which provides evidence-based algorithms for the management of common mental health conditions, including anxiety and sleep disorders. Prescription data and patient characteristics will be extracted from the French national health insurance database (DCIR). The primary outcome is the proportion of new benzodiazepine users whose prescriptions comply with recommended duration guidelines. Multilevel logistic regression models will assess the intervention effect, adjusting for patient- and GP-level factors.
Interventions
OTHERTraining
Training intervention on benzodiazepine prescribing with access to the PsychoMG website providing evidence-based clinical decision algorithms for anxiety and sleep disorder management.
Sponsors
MSPU de Pins-Justaret
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Being a general practitioner or a specialist in general medicine. * Practicing in the Occitanie region. * Working in private practice. * Being registered under Sector 1 fee agreements. * Providing informed consent to participate in the study. * Having computer equipment in the medical office, available during consultation (desktop, laptop, tablet, or smartphone) with internet access.
Exclusion criteria
\- Physicians who have been practicing for less than two years, as they are unlikely to have sufficient retrospective data on prescription reimbursements for their patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compliance with recommended maximum duration of benzodiazepine prescriptions among new users | 12 months | Primary outcome measure: adherence to recommended prescription duration (yes/no) for benzodiazepines A patient is considered to have a prescription duration for benzodiazepines that is either adherent or non-adherent if they had no benzodiazepine exposure in the previous year and their duration of exposure during the first treatment episode: 1. is less than 12 weeks for anxiolytic benzodiazepines, 2. is less than 28 days for hypnotic benzodiazepines and related drugs, in accordance with current recommendations. |
Outcome results
None listed